1. Are the results of this trial consistent with those of observational studies of breast cancer?

2. The incidence of invasive cancer was increased in the E+P arm, but there was no effect on in situ cancers. Also, the cancers in the E+P arm were larger, more likely to be lymphnode positive and metastatic. The E+P group also had higher rates of abnormal mammographic findings after one year of use. Are these findings compatible with an effect of E+P on cancer initiation or cancer promotion?

3. Table 3 shows associations with prior oral contraceptive use, and prior use of HRT. Are there any indications of possible interactions between prior hormone use and current E+P versus placebo?